Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Receivables (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Receivables for 3 consecutive years, with $67000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Receivables fell 54.11% to $67000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $67000.0, a 54.11% decrease, with the full-year FY2025 number at $67000.0, down 54.11% from a year prior.
  • Receivables was $67000.0 for Q4 2025 at Artiva Biotherapeutics, down from $79000.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $1.8 million in Q4 2023 to a low of $30000.0 in Q2 2025.
  • A 3-year average of $559500.0 and a median of $190000.0 in 2024 define the central range for Receivables.
  • Biggest YoY gain for Receivables was 54.11% in 2025; the steepest drop was 97.95% in 2025.
  • Artiva Biotherapeutics' Receivables stood at $1.8 million in 2023, then crashed by 91.7% to $146000.0 in 2024, then crashed by 54.11% to $67000.0 in 2025.
  • Per Business Quant, the three most recent readings for ARTV's Receivables are $67000.0 (Q4 2025), $79000.0 (Q3 2025), and $30000.0 (Q2 2025).